Home
OTLK
OTLK News

Latest Outlook Therapeutics Inc. (OTLK) News on September 18, 2025

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

GlobeNewswire

3 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

Pharmaceutical Technology

3 months ago

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

GlobeNewswire

3 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

GlobeNewswire

4 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

GlobeNewswire

4 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

MT Newswires

4 months ago

Outlook Therapeutics Plans Share Offering; Stock Declines After Hours

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire

4 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

GlobeNewswire

4 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

MT Newswires

5 months ago

Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire

5 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

GlobeNewswire

7 months ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire

7 months ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

GlobeNewswire

7 months ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

GlobeNewswire

7 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

GlobeNewswire

8 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

GlobeNewswire

8 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

GlobeNewswire

8 months ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

MT Newswires

8 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires

8 months ago

Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Benzinga

8 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

GlobeNewswire

8 months ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

GlobeNewswire

8 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss

GuruFocus.com

9 months ago

Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss

Outlook Therapeutics Reports 2024 Financial Results

TipRanks

9 months ago

Outlook Therapeutics Reports 2024 Financial Results

Outlook Therapeutics provides ONS-5010/LYTENAVA update

TipRanks

9 months ago

Outlook Therapeutics provides ONS-5010/LYTENAVA update

MT Newswires

9 months ago

Outlook Therapeutics' Annual Loss Per Share Narrows in FY24; Shares Up

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

GlobeNewswire

9 months ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

MT Newswires

9 months ago

Outlook Therapeutics to Cut 23% Workforce to Lower Costs

Outlook Therapeutics® Streamlines Operations

GlobeNewswire

9 months ago

Outlook Therapeutics® Streamlines Operations

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

GlobeNewswire

9 months ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Executive Leadership Transition

GlobeNewswire

9 months ago

Outlook Therapeutics® Announces Executive Leadership Transition

MT Newswires

10 months ago

Chardan Downgrades Outlook Therapeutics to Neutral From Buy, Puts Price Target 'Under Review' After $53 Price Target

Outlook Therapeutics price target lowered to $9 from $50 at BTIG

TipRanks

10 months ago

Outlook Therapeutics price target lowered to $9 from $50 at BTIG

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

Zacks

10 months ago

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial

Pharmaceutical Technology

10 months ago

Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial

Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial

Clinical Trials Arena

10 months ago

Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Benzinga

10 months ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

MT Newswires

10 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

MT Newswires

10 months ago

Sector Update: Health Care

MT Newswires

10 months ago

Outlook Therapeutics Says Eye Disease Drug Fails Key Trial Endpoint; Shares Plunge

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

GlobeNewswire

10 months ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK),

Simply Wall St.

10 months ago

Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK),

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

GlobeNewswire

10 months ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

GlobeNewswire

a year ago

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/01/2024

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire

a year ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

GlobeNewswire

a year ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

GlobeNewswire

a year ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Thomson Reuters StreetEvents

a year ago

Q3 2024 Outlook Therapeutics Inc Earnings Call

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

GlobeNewswire

a year ago

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now?

Insider Monkey

a year ago

Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now?

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

GlobeNewswire

a year ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

MT Newswires

a year ago

Outlook Therapeutics Receives UK Marketing Authorization for Eye Disease Drug

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

GlobeNewswire

a year ago

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%

Simply Wall St.

a year ago

Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

MT Newswires

a year ago

Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

GlobeNewswire

a year ago

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Thomson Reuters StreetEvents

a year ago

Q2 2024 Outlook Therapeutics Inc Earnings Call

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

GlobeNewswire

a year ago

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

MT Newswires

a year ago

Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire

a year ago

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

GlobeNewswire

a year ago

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

Outlook Therapeutics® to Present at the Retina World Congress 2024

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the Retina World Congress 2024

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

GlobeNewswire

a year ago

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

GlobeNewswire

a year ago

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

Insiders are Piling into These 10 Healthcare Stocks in 2024

Insider Monkey

a year ago

Insiders are Piling into These 10 Healthcare Stocks in 2024

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

GlobeNewswire

a year ago

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

GlobeNewswire

2 years ago

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

GlobeNewswire

2 years ago

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

7 of the Best Speculative Stocks You Can Snag for Less Than $1

InvestorPlace

2 years ago

7 of the Best Speculative Stocks You Can Snag for Less Than $1

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

InvestorPlace

2 years ago

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

GuruFocus.com

2 years ago

Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

GlobeNewswire

2 years ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Eos Energy Enterprises Join Forces with SABIC Specialties to Produce a Specialty Light-Weight, Conductive Composite Thermoplastic for Eos Z3TM Battery

GlobeNewswire

2 years ago

Eos Energy Enterprises Join Forces with SABIC Specialties to Produce a Specialty Light-Weight, Conductive Composite Thermoplastic for Eos Z3TM Battery

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

GlobeNewswire

2 years ago

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

Powerfleet and MiX Telematics Announce Shareholders Meetings to Vote on Proposed Business Combination

PR Newswire

2 years ago

Powerfleet and MiX Telematics Announce Shareholders Meetings to Vote on Proposed Business Combination

Here's What We Like About Peoples Bancorp of North Carolina's (NASDAQ:PEBK) Upcoming Dividend

Simply Wall St.

2 years ago

Here's What We Like About Peoples Bancorp of North Carolina's (NASDAQ:PEBK) Upcoming Dividend

HYZON DELIVERS FIRST FOUR FUEL CELL ELECTRIC VEHICLES TO PERFORMANCE FOOD GROUP

PR Newswire

2 years ago

HYZON DELIVERS FIRST FOUR FUEL CELL ELECTRIC VEHICLES TO PERFORMANCE FOOD GROUP

Associated Press Finance

2 years ago

Alerus: Q4 Earnings Snapshot

Alerus Financial Corp (ALRS) Reports Q4 Loss and Balance Sheet Repositioning

GuruFocus.com

2 years ago

Alerus Financial Corp (ALRS) Reports Q4 Loss and Balance Sheet Repositioning

Alerus Financial Corporation Announces Fourth Quarter 2023 Results, Including Balance Sheet Repositioning

Business Wire

2 years ago

Alerus Financial Corporation Announces Fourth Quarter 2023 Results, Including Balance Sheet Repositioning

Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study

Zacks

2 years ago

Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study

Aemetis Biogas Expands Revenues with First Sale of Low Carbon Fuel Standard Credits

NewMediaWire

2 years ago

Aemetis Biogas Expands Revenues with First Sale of Low Carbon Fuel Standard Credits

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

GlobeNewswire

2 years ago

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010

Hear from Ciaran Long, CFO of a.k.a. Brands Live at ICR Conference 2024

IPO-Edge.com

2 years ago

Hear from Ciaran Long, CFO of a.k.a. Brands Live at ICR Conference 2024

FirstSun, HomeStreet to merge

Banking Dive

2 years ago

FirstSun, HomeStreet to merge

HomeStreet to sell itself after tough year

American Banker

2 years ago

HomeStreet to sell itself after tough year

Armada Hoffler To Discuss Fourth Quarter Earnings On February 22nd

GlobeNewswire

2 years ago

Armada Hoffler To Discuss Fourth Quarter Earnings On February 22nd

LuxUrban Hotels to Present at Upcoming Investor Conferences

Business Wire

2 years ago

LuxUrban Hotels to Present at Upcoming Investor Conferences

The 3 Best Biotech Stocks to Buy in January 2024

InvestorPlace

2 years ago

The 3 Best Biotech Stocks to Buy in January 2024

SKYX Will Debut Its New Patented Game-Changing Smart Home Platforms Technologies at CES 2024 - Opening Today, January 9th in Las Vegas

ACCESSWIRE

2 years ago

SKYX Will Debut Its New Patented Game-Changing Smart Home Platforms Technologies at CES 2024 - Opening Today, January 9th in Las Vegas

Qurate CEO Talks Turnaround and Growth Plans

WWD

2 years ago

Qurate CEO Talks Turnaround and Growth Plans

VIZSLA SILVER ANNOUNCES SIGNIFICANT INCREASE IN CONTAINED OUNCES AND INCREASE IN GRADE OF INDICATED CATEGORY TO 551 G/T AGEQ IN UPDATED MINERAL RESOURCES ESTIMATE

CNW Group

2 years ago

VIZSLA SILVER ANNOUNCES SIGNIFICANT INCREASE IN CONTAINED OUNCES AND INCREASE IN GRADE OF INDICATED CATEGORY TO 551 G/T AGEQ IN UPDATED MINERAL RESOURCES ESTIMATE

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

GlobeNewswire

2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Alimera Completes Recruitment for the Synchronicity Study

GlobeNewswire

2 years ago

Alimera Completes Recruitment for the Synchronicity Study

Share on Social Networks: